Acadia Pharmaceuticals reported $342M in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
ALKERMES USD 480.13M 15.88M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Biogen USD 2.8B 60M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Corcept Therapeutics USD 340.5M 84.35M Sep/2026
Cytokinetics USD 47.6M 19M Sep/2026
Eisai JPY 235.63B 1.3B Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Incyte USD 1.56B 110M Sep/2026
J&J USD 25.4B 89M Sep/2026
Moderna USD 1.31M 98.69M Sep/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Prothena USD 1.01M 50.07M Jun/2026
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026